Clinical Decision Support System To Prevent Toxicity In Patients Treated With Digoxin

Clinical Decision Support System To Prevent Toxicity In Patients Treated With Digoxin

Asunción Albert (University of Valencia, Spain), Antonio J. Serrano (University of Valencia, Spain), Emilio Soria (University of Valencia, Spain) and Nicolás Victor Jiménez (University of Valencia, Spain)
DOI: 10.4018/978-1-60960-561-2.ch416
OnDemand PDF Download:
No Current Special Offers


In this chapter, authors develop a system for prevention and detection of congestive heart failure and fibrillation. Due to its narrow therapeutic range more than 10% of the patients treated with DGX can suffer toxic effects, but it is estimated that half of the cases of digitalis toxicity could be prevented. Two multivariate models were developed to prevent digitalis toxicity.
Chapter Preview


Digoxin is one of the most widely prescribed drugs for the treatment of congestive heart failure and atrial arrhythmia. Despite current guidelines relegate digoxin use to patients that remain symptomatic after receiving optimum doses of antihypertensive and the utility of digoxin in atrial dysrhythmia is only superior to other agents when the patient has associated heart failure.

Digoxin use has decreased significantly from 31.4% (late 2001) to 23.5% in (late 2004) (p<0.00001), the number of toxic or potentially toxic exposures to digoxin requiring hospitalization has not decreased (Hussain, Swindle, & Hauptman, 2006), specially in geriatric patients who uses about 80% of the global consumption of digitalis drugs (Kernan, Castellsague, Perlman, & Ostfeld, 1994; Warren, McBean, Hass, & Babish, 1994).

The Institute for Safe Medication Practices classifies digoxin as a “high alert medication”; that is drugs that bear a heightened risk of causing significant patient harm when they are used in error (High-alert medication list.).

Therefore, digoxin intoxication represents about a fourth of the adverse drug events (ADEs) detected in the geriatric population, which frequently results in hospitalization (Gurwitz et al., 2000). Digoxin is the fourth drug class (7.7%) most frequently involved in potentially preventable adverse drug events at the emergency room (Otero et al., 2006), and one of the ten drugs most frequently associated with medication that demand interdisciplinary (physicians, pharmacists and nurses) actions (Llopis, Albert, Sancho, Calipienso, & Jiménez-Torres, 1999; Markota, Markota, Tomic, & Zelenika, 2009; Mutnick et al., 1997; Rupawala, Kshirsagar, & Gogtay, 2009).

The wide pharmacokinetic and pharmacodynamic variability of digoxin due to its narrow therapeutic range, together with the multiple factors that can affect the organism response to digoxin and the diversity of clinical manifestations of digitalis toxicity (DT), results in digoxin being frequently associated to drug related problems. It is estimated that half of the cases of DT could have been prevented; this gives an opportunity to improve the treatment that patients receive and reduce medical costs (Gandhi, Vlasses, Morton, & Bauman, 1997).

In order to improve efficiency, with the available resources, it is necessary to identify those patients that are most susceptible to profit from pharmaceutical care actions; that is to say, to identify patients with either potential or real drug related problems, in order to prevent the former and resolve the latter. Multivariate statistical methods, as logistic regression and neural networks, are useful tools to develop prediction models of morbidity (toxicity or therapeutic failure) associated to drug use, particularly when factors that influence the therapeutic response are analyzed.

Complete Chapter List

Search this Book: